Abstract:Welcome to the latest issue of Seminars in Thrombosis and Hemostasis (STH); this issue primarily devoted to highlighting the contact activation pathway of coagulation. Developed to provide an overview of the current body of knowledge around the roles, applications, and new knowledge of the contact pathway, this compilation serves as an appetizer for the modern thrombosis and inflammation enthusiast. This issue begins with a contribution from Dr. Shamanaev and colleagues, who start at the top of the coagulation cascade and examine the structure and function of coagulation factor XII (FXII), a serine protease, as it relates to disease.[1] The zymogen FXII can convert prekallikrein and factor XI to the proteases kallikrein and activated FXI (FXIa); this process is instrumental in certain disease states to facilitate abnormal incidents like angioedema and thrombotic events. Drawing on its homolog—pro-hepatocyte growth factor activator—a combination of isolated domains was selected for replacement and then assessed for resulting FXII activation and FXIIa activity. This review acts to establish the circulating closed and bound open conformations of FXII that are resistant to and expedite activation, respectively. Such information may prove integral as we proceed to unravel the complexities of key pathological processes in the quest to ultimately develop treatments for thromboinflammatory disorders. The second manuscript in this issue, by Kearney and colleagues, refocuses the spotlight on plasma kallikrein (PKa) and its additional role within the coagulation cascade in directly activating coagulation factor IX (FIX).[2] Three independent studies corroborate a classic canonical intrinsic pathway (FXII–FXI–FIX) and a noncanonical pathway (PKa–FIX). With the existence of PKa as a coagulation clotting factor established, the next step is the investigation of the products of its cleavage as it relates to the functioning of the body. This manuscript will eventually inform on novel anticoagulant compounds to be researched, tested, and developed for future use. In the third manuscript, Dr. Lira and colleagues shift our attention to coagulation factor XI (FXI)—a zymogen of plasma protease FXIa, which is key in facilitating normal physiological functions and driving some abnormal pathological processes.[3] On top of sharing a convergence history, mirroring PKa, FXI has also been demonstrated to play additional roles, in this case, promoting the generation of thrombin, lending to its versatility in function. Furthermore, FXI activity ventures beyond the intrinsic pathway of coagulation into the world of platelets, endothelial cells, and inflammation. This work summarizes FXI's many responsibilities and informs potential future research directions targeting FXI as a focus for therapeutic intervention. The fourth manuscript, by Vappala and colleagues, highlights fundamental triggers of the contact pathway of coagulation: polyphosphates, DNA, and RNA.[4] More specifically, extracellular DNA in the form of neutrophil extracellular traps (NETs) have been identified as advancing the occurrence and severity of thrombotic events. From that standpoint, this article explores the understood functions of extracellular polyphosphate and nucleic acids in thrombosis, and it ponders the notion of engineering innovative agents designed to target the prothrombotic activities linked to polyphosphate and NETs. Dr. Petersen and colleagues follow with discussion of the C1-inhibitor, which is a vital regulator of the intrinsic coagulation pathway, fibrinolytic system, and complement cascade.[5] The critical loss in level and function of the C1-inhibitor, resulting from a mutation in the SERPING1 gene, gives rise to the rare, genetic disorder known as hereditary angioedema, a condition severely debilitating to patients. Furthermore, C1-inhibitor deficiency is associated with activation of the contact activation cascade and kallikrein–kinin pathway, resulting in undesired vascular leakage. The authors tell the story of hereditary angioedema from the clinical presentation to biological processes, concluding in management options to improve the quality of life for impacted individuals. The final manuscript under the theme of contact activation, by Goel and colleagues, considers a prominent complication of anticoagulant therapy linked to the severity of subsequent bleeding incidents.[6] As such, it is imperative to strike that delicate balance between hemostasis and hemorrhage and especially so for the subset of patients utilizing medical devices, such as extracorporeal devices and central venous catheters. Viable targets for future investigation include FXI, FXII, and prekallikrein, for selective inhibition of these steps within the contact pathway does not overtly affect normal hemostasis. This review consolidates the latest in vivo and clinical data that -Abstract Truncated-

The plasma contact system as a modulator of innate immunity

Contact pathway of coagulation and inflammation

Contact Activation: Where Thrombosis and Hemostasis Meet on a Foreign Surface, Plus a Mini-editorial Compilation ("Part XVI")

Physiologic activities of the contact activation system

Activation and Pharmacological Regulation of Inflammasomes

Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation

The Effects of Coagulation Contact System on Human Vascular Endothelial Cells

Coagulation factor XII in thrombosis and inflammation.

Human Plasma Kallikrein-Kinin System: Physiological and Biochemical Parameters

Novel Insights into the Kallikrein–Kinin System in Fulminant Myocarditis: Physiological Basis and Potential Therapeutic Advances

The Kallikrein-Kinin System: Current and Future Pharmacological Targets

Interaction of Bacteroides fragilis and Bacteroides thetaiotaomicron with the kallikrein–kinin system

A mechanistic model of in vitro plasma activation to evaluate therapeutic kallikrein-kinin system inhibitors

Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis

The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses.

Mutual regulation of CD4+ T cells and intravascular fibrin in infections

The dual role of platelet‐innate immune cell interactions in thrombo‐inflammation

The Crossroads of the Coagulation System and the Immune System: Interactions and Connections

The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications

Platelet Interaction with Innate Immune Cells

Kidney and innate immunity